Literature DB >> 22493497

Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9).

Vikas Sharotri1, Daniel M Collier, Diane R Olson, Ruifeng Zhou, Peter M Snyder.   

Abstract

The epithelial Na(+) channel (ENaC) is critical for Na(+) homeostasis and blood pressure control. Defects in its regulation cause inherited forms of hypertension and hypotension. Previous work found that ENaC gating is regulated by proteases through cleavage of the extracellular domains of the α and γ subunits. Here we tested the hypothesis that ENaC is regulated by proprotein convertase subtilisin/kexin type 9 (PCSK9), a protease that modulates the risk of cardiovascular disease. PCSK9 reduced ENaC current in Xenopus oocytes and in epithelia. This occurred through a decrease in ENaC protein at the cell surface and in the total cellular pool, an effect that did not require the catalytic activity of PCSK9. PCSK9 interacted with all three ENaC subunits and decreased their trafficking to the cell surface by increasing proteasomal degradation. In contrast to its previously reported effects on the LDL receptor, PCSK9 did not alter ENaC endocytosis or degradation of the pool of ENaC at the cell surface. These results support a role for PCSK9 in the regulation of ENaC trafficking in the biosynthetic pathway, likely by increasing endoplasmic reticulum-associated degradation. By reducing ENaC channel number, PCSK9 could modulate epithelial Na(+) absorption, a major contributor to blood pressure control.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22493497      PMCID: PMC3365958          DOI: 10.1074/jbc.M112.363382

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  A pore segment in DEG/ENaC Na(+) channels.

Authors:  P M Snyder; D R Olson; D B Bucher
Journal:  J Biol Chem       Date:  1999-10-01       Impact factor: 5.157

Review 2.  Minireview: regulation of epithelial Na+ channel trafficking.

Authors:  Peter M Snyder
Journal:  Endocrinology       Date:  2005-09-08       Impact factor: 4.736

3.  Cell surface expression of the epithelial Na channel and a mutant causing Liddle syndrome: a quantitative approach.

Authors:  D Firsov; L Schild; I Gautschi; A M Mérillat; E Schneeberger; B C Rossier
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

Review 4.  Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Curr Opin Lipidol       Date:  2005-04       Impact factor: 4.776

5.  Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

Authors:  Kara N Maxwell; Edward A Fisher; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-27       Impact factor: 11.205

6.  An epithelial serine protease activates the amiloride-sensitive sodium channel.

Authors:  V Vallet; A Chraibi; H P Gaeggeler; J D Horisberger; B C Rossier
Journal:  Nature       Date:  1997-10-09       Impact factor: 49.962

7.  Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney.

Authors:  S Masilamani; G H Kim; C Mitchell; J B Wade; M A Knepper
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

8.  Neutrophil elastase activates near-silent epithelial Na+ channels and increases airway epithelial Na+ transport.

Authors:  Ray A Caldwell; Richard C Boucher; M Jackson Stutts
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-01-07       Impact factor: 5.464

9.  Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

Authors:  Sahng Wook Park; Young-Ah Moon; Jay D Horton
Journal:  J Biol Chem       Date:  2004-09-22       Impact factor: 5.157

10.  NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.

Authors:  Suzanne Benjannet; David Rhainds; Rachid Essalmani; Janice Mayne; Louise Wickham; Weijun Jin; Marie-Claude Asselin; Josée Hamelin; Mathilde Varret; Delphine Allard; Mélanie Trillard; Marianne Abifadel; Angie Tebon; Alan D Attie; Daniel J Rader; Catherine Boileau; Louise Brissette; Michel Chrétien; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2004-09-09       Impact factor: 5.157

View more
  24 in total

Review 1.  Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.

Authors:  Giuseppe Danilo Norata; Hagai Tavori; Angela Pirillo; Sergio Fazio; Alberico L Catapano
Journal:  Cardiovasc Res       Date:  2016-08-05       Impact factor: 10.787

Review 2.  PCSK9: From Basic Science Discoveries to Clinical Trials.

Authors:  Michael D Shapiro; Hagai Tavori; Sergio Fazio
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367

Review 3.  On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.

Authors:  Hagai Tavori; Shirya Rashid; Sergio Fazio
Journal:  Atherosclerosis       Date:  2014-12-17       Impact factor: 5.162

4.  Nephrotic Syndrome Complications - New and Old. Part 1.

Authors:  Ruxandra Mihaela Busuioc; Gabriel Mircescu
Journal:  Maedica (Bucur)       Date:  2022-03

Review 5.  PCSK9 and Other Metabolic Targets to Counteract Ischemia/Reperfusion Injury in Acute Myocardial Infarction and Visceral Vascular Surgery.

Authors:  Silvia Ortona; Chiara Barisione; Pier Francesco Ferrari; Domenico Palombo; Giovanni Pratesi
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

6.  Emerging Roles of PCSK9: More Than a One-Trick Pony.

Authors:  Kathryn J Moore; Ira J Goldberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-02       Impact factor: 8.311

7.  Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima-media thickness in hypertensives.

Authors:  Sheng-Hua Yang; Ying Du; Sha Li; Yan Zhang; Rui-Xia Xu; Cheng-Gang Zhu; Yuan-Lin Guo; Na-Qiong Wu; Qian Dong; Jing Sun; Jian-Jun Li
Journal:  Hypertens Res       Date:  2016-04-14       Impact factor: 3.872

8.  PCSK9Qβ-003 Vaccine Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice.

Authors:  Danyu Wu; Yajie Pan; Shijun Yang; Chang Li; Yanzhao Zhou; Yingxuan Wang; Xiao Chen; Zihua Zhou; Yuhua Liao; Zhihua Qiu
Journal:  Cardiovasc Drugs Ther       Date:  2020-07-28       Impact factor: 3.727

Review 9.  The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.

Authors:  Steve Poirier; Gaétan Mayer
Journal:  Drug Des Devel Ther       Date:  2013-10-04       Impact factor: 4.162

Review 10.  Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.

Authors:  Marianne Abifadel; Sandy Elbitar; Petra El Khoury; Youmna Ghaleb; Mélody Chémaly; Marie-Line Moussalli; Jean-Pierre Rabès; Mathilde Varret; Catherine Boileau
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.